{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T04:40:18Z","timestamp":1680756018366},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00393-022-01311-4","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T12:07:02Z","timestamp":1673006822000},"page":"187-194","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rheumatologische Nebenwirkungen von Checkpointinhibitoren und deren Behandlung","Rheumatological side effects of checkpoint inhibitors and their treatment"],"prefix":"10.1007","volume":"82","author":[{"given":"Lea","family":"Gr\u00fcmme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"issue":"4","key":"1311_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/rheumatology\/kex470","volume":"57","author":"J Albayda","year":"2018","unstructured":"Albayda\u00a0J, Bingham\u00a0CO 3rd, Shah\u00a0AA, Kelly\u00a0RJ, Cappelli\u00a0L (2018) Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatology (Oxford) 57(4):760\u2013762. https:\/\/doi.org\/10.1093\/rheumatology\/kex470","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1311_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/acr2.1026","volume":"1","author":"J Albayda","year":"2019","unstructured":"Albayda\u00a0J, Dein\u00a0E, Shah\u00a0AA, Bingham\u00a0CO 3rd, Cappelli\u00a0L (2019) Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: a case series. ACR Open Rheumatol 1(5):303\u2013307. https:\/\/doi.org\/10.1002\/acr2.1026","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"1311_CR3","doi-asserted-by":"publisher","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","volume":"19","author":"Y Allenbach","year":"2020","unstructured":"Allenbach\u00a0Y, Anquetil\u00a0C, Manouchehri\u00a0A, Benveniste\u00a0O, Lambotte\u00a0O, Lebrun-Vignes\u00a0B, Spano\u00a0JP, Ederhy\u00a0S, Klatzmann\u00a0D, Rosenzwajg\u00a0M, Fautrel\u00a0B, Cadranel\u00a0J, Johnson\u00a0DB, Moslehi\u00a0JJ, Salem\u00a0JE (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19(8):102586. https:\/\/doi.org\/10.1016\/j.autrev.2020.102586","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1311_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","volume":"41","author":"F Angelopoulou","year":"2021","unstructured":"Angelopoulou\u00a0F, Bogdanos\u00a0D, Dimitroulas\u00a0T, Sakkas\u00a0L, Daoussis\u00a0D (2021) Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol Int 41(1):33\u201342. https:\/\/doi.org\/10.1007\/s00296-020-04665-7","journal-title":"Rheumatol Int"},{"issue":"10","key":"1311_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","volume":"76","author":"R Belkhir","year":"2017","unstructured":"Belkhir\u00a0R, Burel\u00a0SL, Dunogeant\u00a0L, Marabelle\u00a0A, Hollebecque\u00a0A, Besse\u00a0B, Leary\u00a0A, Voisin\u00a0AL, Pontoizeau\u00a0C, Coutte\u00a0L, Pertuiset\u00a0E, Mouterde\u00a0G, Fain\u00a0O, Lambotte\u00a0O, Mariette\u00a0X (2017) Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76(10):1747\u20131750. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211216","journal-title":"Ann Rheum Dis"},{"key":"1311_CR6","doi-asserted-by":"publisher","first-page":"114147","DOI":"10.1016\/j.bcp.2020.114147","volume":"180","author":"S Bindu","year":"2020","unstructured":"Bindu\u00a0S, Mazumder\u00a0S, Bandyopadhyay\u00a0U (2020) Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol 180:114147. https:\/\/doi.org\/10.1016\/j.bcp.2020.114147","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1311_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca\u00a0MP, Olenchock\u00a0BA, Salem\u00a0JE, Wiviott\u00a0SD, Ederhy\u00a0S, Cohen\u00a0A, Stewart\u00a0GC, Choueiri\u00a0TK, Di Carli\u00a0M, Allenbach\u00a0Y, Kumbhani\u00a0DJ, Heinzerling\u00a0L, Amiri-Kordestani\u00a0L, Lyon\u00a0AR, Thavendiranathan\u00a0P, Padera\u00a0R, Lichtman\u00a0A, Liu\u00a0PP, Johnson\u00a0DB, Moslehi\u00a0J (2019) Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140(2):80\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034497","journal-title":"Circulation"},{"issue":"17","key":"1311_CR8","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer\u00a0JR, Lacchetti\u00a0C, Schneider\u00a0BJ, Atkins\u00a0MB, Brassil\u00a0KJ, Caterino\u00a0JM, Chau\u00a0I, Ernstoff\u00a0MS, Gardner\u00a0JM, Ginex\u00a0P, Hallmeyer\u00a0S, Holter Chakrabarty\u00a0J, Leighl\u00a0NB, Mammen\u00a0JS, McDermott\u00a0DF, Naing\u00a0A, Nastoupil\u00a0LJ, Phillips\u00a0T, Porter\u00a0LD, Puzanov\u00a0I, Reichner\u00a0CA, Santomasso\u00a0BD, Seigel\u00a0C, Spira\u00a0A, Suarez-Almazor\u00a0ME, Wang\u00a0Y, Weber\u00a0JS, Wolchok\u00a0JD, Thompson\u00a0JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J\u00a0Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"1","key":"1311_CR9","doi-asserted-by":"publisher","first-page":"e000906","DOI":"10.1136\/rmdopen-2019-000906","volume":"5","author":"C Calabrese","year":"2019","unstructured":"Calabrese\u00a0C, Cappelli\u00a0LC, Kostine\u00a0M, Kirchner\u00a0E, Braaten\u00a0T, Calabrese\u00a0L (2019) Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open 5(1):e906. https:\/\/doi.org\/10.1136\/rmdopen-2019-000906","journal-title":"RMD Open"},{"issue":"1","key":"1311_CR10","doi-asserted-by":"publisher","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"C Calabrese","year":"2017","unstructured":"Calabrese\u00a0C, Kirchner\u00a0E, Kontzias\u00a0A, Velcheti\u00a0V, Calabrese\u00a0LH (2017) Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a\u00a0new nosological entity. RMD Open 3(1):e412. https:\/\/doi.org\/10.1136\/rmdopen-2016-000412 (Erratum in: RMD Open. 2017 Dec 6;3(2):e000412corr1. Kontzias, K [corrected to Kontzias, A]. PMID: 28405474; PMCID: PMC5372131.)","journal-title":"RMD Open"},{"issue":"1","key":"1311_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli\u00a0LC, Gutierrez\u00a0AK, Baer\u00a0AN, Albayda\u00a0J, Manno\u00a0RL, Haque\u00a0U, Lipson\u00a0EJ, Bleich\u00a0KB, Shah\u00a0AA, Naidoo\u00a0J, Brahmer\u00a0JR, Le\u00a0D, Bingham\u00a0CO 3rd (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76(1):43\u201350. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209595","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1311_CR12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli\u00a0LC, Gutierrez\u00a0AK, Bingham\u00a0CO 3rd, Shah\u00a0AA (2017) Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken) 69(11):1751\u20131763. https:\/\/doi.org\/10.1002\/acr.23177 (Epub 2017 Sep 21. PMID: 27998041; PMCID: PMC5478477)","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1311_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","volume":"158","author":"N Chanson","year":"2021","unstructured":"Chanson\u00a0N, Ramos-Casals\u00a0M, Pundole\u00a0X, Suijkerbuijk\u00a0K, Jos\u00e9 de Barros E Silva\u00a0M, Lidar\u00a0M, Benesova\u00a0K, Leipe\u00a0J, Acar-Denizli\u00a0N, Prad\u00e8re\u00a0P, Michot\u00a0JM, Voisin\u00a0AL, Su\u00e1rez-Almazor\u00a0ME, Radstake\u00a0TRD, Fernandes Mo\u00e7a Trevisani\u00a0V, Schulze-Koops\u00a0H, Melin\u00a0A, Robert\u00a0C, Mariette\u00a0X, Baughman\u00a0RP, Lambotte\u00a0O (2021) Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. Eur J Cancer 158:208\u2013216. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.041","journal-title":"Eur J Cancer"},{"issue":"3","key":"1311_CR14","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s10072-021-05561-z","volume":"43","author":"L Diamanti","year":"2022","unstructured":"Diamanti\u00a0L, Picca\u00a0A, Bini\u00a0P, Gastaldi\u00a0M, Alfonsi\u00a0E, Pichiecchio\u00a0A, Rota\u00a0E, Rud\u00e0\u00a0R, Bruno\u00a0F, Villani\u00a0V, Gali\u00e8\u00a0E, Vogrig\u00a0A, Valente\u00a0M, Zoccarato\u00a0M, Poretto\u00a0V, Giometto\u00a0B, Cimminiello\u00a0C, Del Vecchio\u00a0M, Marchioni\u00a0E (2022) Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. Neurol Sci 43(3):2031\u20132041. https:\/\/doi.org\/10.1007\/s10072-021-05561-z","journal-title":"Neurol Sci"},{"issue":"6","key":"1311_CR15","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood\u00a0B, Najafi\u00a0M, Mortezaee\u00a0K (2019) CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J\u00a0Cell Physiol 234(6):8509\u20138521. https:\/\/doi.org\/10.1002\/jcp.27782","journal-title":"J Cell Physiol"},{"issue":"11","key":"1311_CR16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/art.41036","volume":"71","author":"J Feist","year":"2019","unstructured":"Feist\u00a0J, Murray\u00a0A, Skapenko\u00a0A, Schulze-Koops\u00a0H (2019) A rare side effect of checkpoint inhibitor therapy-nivolumab-induced axial polyarthritis of the facet and costovertebral joints. Arthritis Rheumatol 71(11):1823. https:\/\/doi.org\/10.1002\/art.41036","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1311_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","volume":"39","author":"J Galon","year":"2013","unstructured":"Galon\u00a0J, Angell\u00a0HK, Bedognetti\u00a0D, Marincola\u00a0FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39(1):11\u201326. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.008","journal-title":"Immunity"},{"issue":"12","key":"1311_CR18","doi-asserted-by":"publisher","first-page":"803410","DOI":"10.3389\/fimmu.2021.803410","volume":"6","author":"N Hamada","year":"2021","unstructured":"Hamada\u00a0N, Maeda\u00a0A, Takase-Minegishi\u00a0K, Kirino\u00a0Y, Sugiyama\u00a0Y, Namkoong\u00a0H, Horita\u00a0N, Yoshimi\u00a0R, Nakajima\u00a0H (2021) Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol 6(12):803410. https:\/\/doi.org\/10.3389\/fimmu.2021.803410","journal-title":"Front Immunol"},{"issue":"9","key":"1311_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1136\/jech.2006.051292","volume":"61","author":"K Heikkil\u00e4","year":"2007","unstructured":"Heikkil\u00e4\u00a0K, Ebrahim\u00a0S, Lawlor\u00a0DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J\u00a0Epidemiol Community Health 61(9):824\u2013833. https:\/\/doi.org\/10.1136\/jech.2006.051292","journal-title":"J Epidemiol Community Health"},{"key":"1311_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3238\/arztebl.2019.0119","volume":"116","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling\u00a0L, De Toni\u00a0E, Schett\u00a0G, Hundorfean\u00a0G, Zimmer\u00a0L (2019) Checkpoint inhibitors\u2014the diagnosis and treatment of side effects. Dtsch Arztebl Int 116:119\u2013126. https:\/\/doi.org\/10.3238\/arztebl.2019.0119","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"1311_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","volume":"120","author":"L Hirsch","year":"2019","unstructured":"Hirsch\u00a0L, Zitvogel\u00a0L, Eggermont\u00a0A, Marabelle\u00a0A (2019) PD-Loma: a\u00a0cancer entity with a\u00a0shared sensitivity to the PD-1\/PD-L1 pathway blockade. Br J Cancer 120(1):3\u20135. https:\/\/doi.org\/10.1038\/s41416-018-0294-4","journal-title":"Br J Cancer"},{"issue":"4","key":"1311_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1017\/s0317167100007939","volume":"36","author":"G Hunter","year":"2009","unstructured":"Hunter\u00a0G, Voll\u00a0C, Robinson\u00a0CA (2009) Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 36(4):518\u2013520. https:\/\/doi.org\/10.1017\/s0317167100007939","journal-title":"Can J Neurol Sci"},{"issue":"suppl_1","key":"1311_CR23","doi-asserted-by":"publisher","first-page":"ehx502.P2612","DOI":"10.1093\/eurheartj\/ehx502.P2612","volume":"38","author":"J Schmid","year":"2017","unstructured":"Schmid\u00a0J, Birner-Gruenberger\u00a0R, Liesinger\u00a0L, Stojakovic\u00a0T, Scharnagl\u00a0H, Dieplinger\u00a0B, Asslaber\u00a0M, Radl\u00a0R, Polacin\u00a0M, Beer\u00a0M, Szolar\u00a0D, Quasthoff\u00a0S, Binder\u00a0JS, Rainer\u00a0P (2017) P2612. Elevated cardiac troponin T but not troponin I in patients with skeletal muscle disease. Eur Heart\u00a0J 38(suppl_1):ehx502.P2612. https:\/\/doi.org\/10.1093\/eurheartj\/ehx502.P2612","journal-title":"Eur Heart J"},{"issue":"1","key":"1311_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.4102\/sajr.v22i1.1316","volume":"22","author":"K Kgoebane","year":"2018","unstructured":"Kgoebane\u00a0K, Ally\u00a0MMTM, Duim-Beytell\u00a0MC, Suleman\u00a0FE (2018) The role of imaging in rheumatoid arthritis. S\u00a0Afr J Radiol 22(1):1316. https:\/\/doi.org\/10.4102\/sajr.v22i1.1316","journal-title":"S Afr J Radiol"},{"issue":"1","key":"1311_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","volume":"80","author":"M Kostine","year":"2021","unstructured":"Kostine\u00a0M, Finckh\u00a0A, Bingham\u00a0CO, Visser\u00a0K, Leipe\u00a0J, Schulze-Koops\u00a0H, Choy\u00a0EH, Benesova\u00a0K, Radstake\u00a0TRDJ, Cope\u00a0AP, Lambotte\u00a0O, Gottenberg\u00a0JE, Allenbach\u00a0Y, Visser\u00a0M, Rusthoven\u00a0C, Thomasen\u00a0L, Jamal\u00a0S, Marabelle\u00a0A, Larkin\u00a0J, Haanen\u00a0JBAG, Calabrese\u00a0LH, Mariette\u00a0X, Schaeverbeke\u00a0T (2021) EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 80(1):36\u201348. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217139","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 7","key":"1311_CR26","doi-asserted-by":"publisher","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","volume":"58","author":"M Kostine","year":"2019","unstructured":"Kostine\u00a0M, Truchetet\u00a0ME, Schaeverbeke\u00a0T (2019) Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (Oxford) 58(Suppl 7):vii68\u2013vii74. https:\/\/doi.org\/10.1093\/rheumatology\/kez295","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1311_CR27","doi-asserted-by":"publisher","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","volume":"4","author":"J Leipe","year":"2018","unstructured":"Leipe\u00a0J, Christ\u00a0LA, Arnoldi\u00a0AP, Mille\u00a0E, Berger\u00a0F, Heppt\u00a0M, Goldscheider\u00a0I, Kauffmann-Guerrero\u00a0D, Huber\u00a0RM, Dechant\u00a0C, Berking\u00a0C, Schulze-Koops\u00a0H, Skapenko\u00a0A (2018) Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 4(2):e714. https:\/\/doi.org\/10.1136\/rmdopen-2018-000714","journal-title":"RMD Open"},{"issue":"13","key":"1311_CR28","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.297.13.1478","volume":"297","author":"ME Margaretten","year":"2007","unstructured":"Margaretten\u00a0ME, Kohlwes\u00a0J, Moore\u00a0D, Bent\u00a0S (2007) Does this adult patient have septic arthritis? JAMA 297(13):1478\u20131488. https:\/\/doi.org\/10.1001\/jama.297.13.1478","journal-title":"JAMA"},{"issue":"2","key":"1311_CR29","doi-asserted-by":"publisher","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","volume":"19","author":"A Matas-Garc\u00eda","year":"2020","unstructured":"Matas-Garc\u00eda\u00a0A, Milisenda\u00a0JC, Selva-O\u2019Callaghan\u00a0A, Prieto-Gonz\u00e1lez\u00a0S, Padrosa\u00a0J, Cabrera\u00a0C, Reguart\u00a0N, Castrej\u00f3n\u00a0N, Sol\u00e9\u00a0M, Ros\u00a0J, Trallero-Araguas\u00a0E, Antoniol\u00a0MN, Vila-Pijoan\u00a0G, Grau\u00a0JM (2020) Emerging PD\u20111 and PD-1L inhibitors-associated myopathy with a\u00a0characteristic histopathological pattern. Autoimmun Rev 19(2):102455. https:\/\/doi.org\/10.1016\/j.autrev.2019.102455","journal-title":"Autoimmun Rev"},{"issue":"19","key":"1311_CR30","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.2017.5283","volume":"317","author":"TE McAlindon","year":"2017","unstructured":"McAlindon\u00a0TE, LaValley\u00a0MP, Harvey\u00a0WF, Price\u00a0LL, Driban\u00a0JB, Zhang\u00a0M, Ward\u00a0RJ (2017) Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317(19):1967\u20131975. https:\/\/doi.org\/10.1001\/jama.2017.5283","journal-title":"JAMA"},{"key":"1311_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","volume":"105","author":"EL Mitchell","year":"2018","unstructured":"Mitchell\u00a0EL, Lau\u00a0PKH, Khoo\u00a0C, Liew\u00a0D, Leung\u00a0J, Liu\u00a0B, Rischin\u00a0A, Frauman\u00a0AG, Kee\u00a0D, Smith\u00a0K, Brady\u00a0B, Rischin\u00a0D, Gibson\u00a0A, Mileshkin\u00a0L, Klein\u00a0O, Weickhardt\u00a0A, Arulananda\u00a0S, Shackleton\u00a0M, McArthur\u00a0G, \u00d6st\u00f6r\u00a0A, Cebon\u00a0J, Solomon\u00a0B, Buchanan\u00a0RR, Wicks\u00a0IP, Lo\u00a0S, Hicks\u00a0RJ, Sandhu\u00a0S (2018) Rheumatic immune-related adverse events secondary to anti-programmed death\u20111 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. Eur J Cancer 105:88\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.027","journal-title":"Eur J Cancer"},{"issue":"6","key":"1311_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","volume":"22","author":"J Naidoo","year":"2017","unstructured":"Naidoo\u00a0J, Cappelli\u00a0LC, Forde\u00a0PM, Marrone\u00a0KA, Lipson\u00a0EJ, Hammers\u00a0HJ, Sharfman\u00a0WH, Le\u00a0DT, Baer\u00a0AN, Shah\u00a0AA, Albayda\u00a0J, Manno\u00a0RL, Haque\u00a0U, Gutierrez\u00a0AK, Bingham\u00a0CO 3rd, Brahmer\u00a0JR (2017) Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist 22(6):627\u2013630. https:\/\/doi.org\/10.1634\/theoncologist.2016-0390","journal-title":"Oncologist"},{"issue":"10","key":"1311_CR33","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","volume":"17","author":"J Narv\u00e1ez","year":"2018","unstructured":"Narv\u00e1ez\u00a0J, Juarez-L\u00f3pez\u00a0P, LLuch\u00a0J, Narv\u00e1ez\u00a0JA, Palmero\u00a0R, Garc\u00eda Del Muro\u00a0X, Nolla\u00a0JM, Domingo-Domenech\u00a0E (2018) Rheumatic immune-related adverse events in patients on anti-PD\u20111 inhibitors: Fasciitis with myositis syndrome as a\u00a0new complication of immunotherapy. Autoimmun Rev 17(10):1040\u20131045. https:\/\/doi.org\/10.1016\/j.autrev.2018.05.002","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1311_CR34","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1136\/annrheumdis-2020-217018","volume":"81","author":"T Nguy\u1ec5n","year":"2022","unstructured":"Nguy\u1ec5n\u00a0T, Maria\u00a0ATJ, Ladhari\u00a0C, Palassin\u00a0P, Quantin\u00a0X, Lesage\u00a0C, Ta\u00efeb\u00a0G, Ayrignac\u00a0X, Rullier\u00a0P, Hillaire-Buys\u00a0D, Lambotte\u00a0O, Guilpain\u00a0P, Faillie\u00a0JL (2022) Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO\u2019s adverse drug reactions database. Ann Rheum Dis 81(2):e32. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1311_CR35","first-page":"114","volume":"37","author":"M Ramos-Casals","year":"2019","unstructured":"Ramos-Casals\u00a0M, Maria\u00a0A, Su\u00e1rez-Almazor\u00a0ME, Lambotte\u00a0O, Fisher\u00a0BA, Hern\u00e1ndez-Molina\u00a0G, Guilpain\u00a0P, Pundole\u00a0X, Flores-Ch\u00e1vez\u00a0A, Baldini\u00a0C, Bingham Iii\u00a0CO, Brito-Zer\u00f3n\u00a0P, Gottenberg\u00a0JE, Kostine\u00a0M, Radstake\u00a0TRD, Schaeverbeke\u00a0T, Schulze-Koops\u00a0H, Calabrese\u00a0L, Khamashta\u00a0MA, Mariette\u00a0X (2019) Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol 37(3):114\u2013122","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1311_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","volume":"38","author":"J Roberts","year":"2019","unstructured":"Roberts\u00a0J, Smylie\u00a0M, Walker\u00a0J, Basappa\u00a0NS, Chu\u00a0Q, Kolinsky\u00a0M, Lyddell\u00a0C, Ye\u00a0C (2019) Hydroxychloroquine is a\u00a0safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 38(5):1513\u20131519. https:\/\/doi.org\/10.1007\/s10067-019-04451-2","journal-title":"Clin Rheumatol"},{"issue":"23","key":"1311_CR37","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.3390\/cancers13236141","volume":"13","author":"LM Serna-Higuita","year":"2021","unstructured":"Serna-Higuita\u00a0LM, Amaral\u00a0T, Forschner\u00a0A, Leiter\u00a0U, Flatz\u00a0L, Seeber\u00a0O, Thomas\u00a0I, Garbe\u00a0C, Eigentler\u00a0TK, Martus\u00a0P (2021) Association between immune-related adverse events and survival in 319 stage IV melanoma patients treated with PD-1-based immunotherapy: an approach based on clinical chemistry. Cancers (Basel) 13(23):6141. https:\/\/doi.org\/10.3390\/cancers13236141","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1311_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","volume":"151","author":"S Sheik Ali","year":"2015","unstructured":"Sheik Ali\u00a0S, Goddard\u00a0AL, Luke\u00a0JJ, Donahue\u00a0H, Todd\u00a0DJ, Werchniak\u00a0A, Vleugels\u00a0RA (2015) Drug-associated dermatomyositis following ipilimumab therapy: a\u00a0novel immune-mediated adverse event associated with cytotoxic T\u2011lymphocyte antigen 4 blockade. JAMA Dermatol 151(2):195\u2013199. https:\/\/doi.org\/10.1001\/jamadermatol.2014.2233","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1311_CR39","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison\u00a0A, Qu\u00e9r\u00e9\u00a0G, Misery\u00a0L, Funck-Brentano\u00a0E, Danlos\u00a0FX, Routier\u00a0E, Robert\u00a0C, Loriot\u00a0Y, Lambotte\u00a0O, Bonniaud\u00a0B, Scalbert\u00a0C, Maanaoui\u00a0S, Lesimple\u00a0T, Martinez\u00a0S, Marcq\u00a0M, Chouaid\u00a0C, Dubos\u00a0C, Brunet-Possenti\u00a0F, Stavris\u00a0C, Chiche\u00a0L, Beneton\u00a0N, Mansard\u00a0S, Guisier\u00a0F, Doubre\u00a0H, Skowron\u00a0F, Aubin\u00a0F, Zehou\u00a0O, Roge\u00a0C, Lambert\u00a0M, Pham-Ledard\u00a0A, Beylot-Barry\u00a0M, Veillon\u00a0R, Kramkimel\u00a0N, Giacchero\u00a0D, De Quatrebarbes\u00a0J, Michel\u00a0C, Auliac\u00a0JB, Gonzales\u00a0G, Decroisette\u00a0C, Le Garff\u00a0G, Carpiuc\u00a0I, Vallerand\u00a0H, Nowak\u00a0E, Cornec\u00a0D, Kostine\u00a0M (2019) Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: A nationwide, multicenter cohort study. Arthritis Rheumatol 71(12):2100\u20132111. https:\/\/doi.org\/10.1002\/art.41068","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1311_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian\u00a0SL, Drake\u00a0CG, Pardoll\u00a0DM (2015) Immune checkpoint blockade: A\u00a0common denominator approach to cancer therapy. Cancer Cell 27(4):450\u2013461. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001","journal-title":"Cancer Cell"},{"issue":"9","key":"1311_CR41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei\u00a0SC, Duffy\u00a0CR, Allison\u00a0JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"issue":"2","key":"1311_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow\u00a0MA, Sidlow\u00a0R, Hellmann\u00a0MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N\u00a0Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01311-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T16:32:19Z","timestamp":1680712339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01311-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1311"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01311-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"assertion":[{"value":"23 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Gr\u00fcmme und H.\u00a0Schulze-Koops geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}